Oncology Archives - Page 19 of 23

Treatment patterns and outcomes for patients with unresectable stage III and Metastatic Melanoma in the USA

Authors: A Tarhini, C Atzinger, K Gupte-Singh, C Johnson, C Macahilig, S Rao Published: Journal of Comparitive Effectiveness Research, 2019 View publication Aim To describe treatment patterns and outcomes of patients with...

A quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis of nivolumab versus everolimus in advanced renal cell carcinoma (aRCC)

Authors: R Shah, M Botteman, C T Solem, L Luo, J Doan, D Cella, R J Motzer Published: Clinical Genitourinary Cancer, 2019 View publication Background This analysis compared quality-adjusted time without symptoms...

OPEN Health – committed to patient outcomes in rare oncology

OPEN Health are delighted to be supporting the rare oncology edition of rare revolution magazine. In our supplement you will find articles written by representatives from across our practices; all focused on...

Looking back at ASCO 2019

Fresh off the back of a busy ASCO 2019, Sean McGrath (Director of Oncology at OPEN Health) had a few moments to pause and answer our pressing questions about his experience: So,...

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV): a trial-based analysis

Authors: M Botteman, K Nickel, S Corman, M Turini, G Binder Published: Supportive care in cancer: Official journal of the Multinational Association of Supportive Care in Cancer, 2019 View publication Purpose To...

Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting

Authors: S H Park, G Binder, S Corman, M Botteman Published: Journal of Medical Economics, 2019 View publication Background Chemotherapy-induced nausea and vomiting (CINV) are among the most common and debilitating side...

Lost Annual Productivity Costs Due to Uterine Cancer Deaths in the United States in 2014

Authors: S Corman, C Nwankwo Published: Journal of Women's Health, 2019 View publication BACKGROUND An estimated 11,350 uterine cancer deaths are projected to occur in the United States in 2018. We constructed...

Overall survival, costs, and healthcare resource use by line of therapy in medicare patients with newly diagnosed metastatic urothelial carcinoma

Authors: A Aly, C Johnson, S Yang, M F Botteman, S Rao, A Hussain. Published: Journal of Medical Economics, 2019 View publication Aims Medicare patients with metastatic or surgically unresectable urothelial carcinoma...

Health state utilities for acute myeloid leukaemia: a time trade-off study

Authors: N Joshi, M Hensen, S Patel, W Xu, K Lasch, E Stolk Published: Pharmacoeconomics, 2019 View publication Objectives Acute myeloid leukaemia (AML) is an aggressive haematological cancer associated with significant humanistic...

News